The Anti-Wolbachia (A·WOL) Consortium has developed both in vitro and in vivo assays, to screen chemical libraries for anti-Wolbachia activity. 

In both the lab and the field, A∙WOL are working to refine existing antibiotics to establish the best possible course of treatment which is practical for use within control programmes for human filariasis. We are also researching entirely new drugs to provide alternative treatments for human filariasis to beat resistance and to ensure that the long-term goal of global elimination of this public health problem is achieved.